scholarly journals Risk of diabetes associated with fatty acids in the de novo lipogenesis pathway is independent of insulin sensitivity and response: the Insulin Resistance Atherosclerosis Study (IRAS)

2019 ◽  
Vol 7 (1) ◽  
pp. e000691 ◽  
Author(s):  
Waqas Qureshi ◽  
Ingrid D Santaren ◽  
Anthony J Hanley ◽  
Steven M Watkins ◽  
Carlos Lorenzo ◽  
...  

ObjectiveTo examine the associations of fatty acids in the de novo lipogenesis (DNL) pathway, specifically myristic acid (14:0), palmitic acid (16:0),cis-palmitoleic acid (c16:1 n-7),cis-myristoleic acid (c14:1n5), stearic acid (18:0) andcis-oleic acid (c18:1 n-9), with 5-year risk of type 2 diabetes. We hypothesized that DNL fatty acids are associated with risk of type 2 diabetes independent of insulin sensitivity.Research design and methodsWe evaluated 719 (mean age 55.1±8.5 years, 44.2% men, 42.3% Caucasians) participants from the Insulin Resistance Atherosclerosis Study. Multivariable logistic regression models with and without adjustment of insulin sensitivity were used to assess prospective associations of DNL fatty acids with incident type 2 diabetes.ResultsType 2 diabetes incidence was 20.3% over 5 years. In multivariable regression models, palmitic, palmitoleic, myristic, myristoleic and oleic acids were associated with increased risk of type 2 diabetes (p<0.05). Palmitic acid had the strongest association (OR per standard unit of palmitic acid 1.46; 95% CI 1.23 to 1.76; p<0.001), which remained similar with addition of insulin sensitivity and acute insulin response (AIR) to the model (OR 1.36; 95% CI 1.09 to 1.70, p=0.01). Oleic and palmitoleic acids were also independently associated with incident type 2 diabetes. In multivariable models, ratios of fatty acids corresponding to stearoyl CoA desaturase-1 and Elovl6 enzymatic activity were significantly associated with risk of type 2 diabetes independent of insulin sensitivity and AIR.ConclusionsWe observed associations of DNL fatty acids with type 2 diabetes incidence independent of insulin sensitivity.

PLoS Medicine ◽  
2020 ◽  
Vol 17 (6) ◽  
pp. e1003102 ◽  
Author(s):  
Fumiaki Imamura ◽  
Amanda M. Fretts ◽  
Matti Marklund ◽  
Andres V. Ardisson Korat ◽  
Wei-Sin Yang ◽  
...  

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Heidi Lai ◽  
Fumiaki Imamura ◽  
Andres Ardisson Korat ◽  
Rachel Murphy ◽  
Nathan Tintle ◽  
...  

Abstract Objectives To assess prospective association between circulating biomarkers of individual trans fatty acids (TFAs) and incident type 2 diabetes (T2D) in diverse populations. Methods A harmonized analysis of individual level data was conducted for TFA biomarkers and incident T2D by pooling ten prospective cohort or nested-case-control studies from five countries (Australia, Germany, Iceland, UK, and USA). Fatty acids (FAs) were measured in plasma phospholipid, red blood cell membrane phospholipid, or total plasma collected between 1990–2008 from 22,711 participants aged ≥18 years without prevalent diabetes. Evaluated TFAs included trans-16:1n-9, sum of trans-18:1 isomers (trans-18:1n6 to trans-18:1n12), sum of trans-18:2 isomers (cis/trans-18:2, trans/cis-18:2, trans/trans-18:2), and individual trans-18:2 isomers. The multivariable-adjusted relative risk or odds ratio was estimated in each cohort by lipid compartments using a pre-specified protocol for definitions of exposures, covariates, and outcomes for statistical analysis. Association estimates were pooled using fixed-effects inverse-variance weighted meta-analysis. Results During an average maximum of 14 years of follow-up, 2244 cases of incident T2D were identified. Median levels of TFAs across cohorts were 0.05–0.18% total FAs for trans-16:1n-9, 0.09–2.05% for total trans-18:1, 0.10–0.73% for total trans-18:2, and 0.01–0.36% for individual trans-18:2 isomers. In overall pooled analysis, TFAs evaluated per inter-quintile range were not significantly associated with risk of T2D (Figure 1). Findings were consistent when TFAs were assessed categorically in study specific-quintiles, and when associations were pooled within lipid compartment (i.e., phospholipids vs. total plasma). Conclusions Overall, biomarker levels of TFAs were not significantly associated with risk of incident T2D in this international pooling project. Findings may be due to mixed TFA sources (industrial vs. ruminant), a general decline in TFA exposure during this period, or no effect of circulating TFA on diabetes. Associations of TFA biomarkers with T2D at higher exposures should be investigated. Funding Sources See Table 1. Supporting Tables, Images and/or Graphs


Metabolomics ◽  
2020 ◽  
Vol 16 (1) ◽  
Author(s):  
David Balgoma ◽  
Sofia Zelleroth ◽  
Alfhild Grönbladh ◽  
Mathias Hallberg ◽  
Curt Pettersson ◽  
...  

Abstract Introduction The abuse of anabolic androgenic steroids (AASs) is a source of public concern because of their adverse effects. Supratherapeutic doses of AASs are known to be hepatotoxic and regulate the lipoproteins in plasma by modifying the metabolism of lipids in the liver, which is associated with metabolic diseases. However, the effect of AASs on the profile of lipids in plasma is unknown. Objectives To describe the changes in the plasma lipidome exerted by AASs and to discuss these changes in the light of previous research about AASs and de novo lipogenesis in the liver. Methods We treated male Wistar rats with supratherapeutic doses of nandrolone decanoate and testosterone undecanoate. Subsequently, we isolated the blood plasma and performed lipidomics analysis by liquid chromatography-high resolution mass spectrometry. Results Lipid profiling revealed a decrease of sphingolipids and glycerolipids with palmitic, palmitoleic, stearic, and oleic acids. In addition, lipid profiling revealed an increase in free fatty acids and glycerophospholipids with odd-numbered chain fatty acids and/or arachidonic acid. Conclusion The lipid profile presented herein reports the imprint of AASs on the plasma lipidome, which mirrors the downregulation of de novo lipogenesis in the liver. In a broader perspective, this profile will help to understand the influence of androgens on the lipid metabolism in future studies of diseases with dysregulated lipogenesis (e.g. type 2 diabetes, fatty liver disease, and hepatocellular carcinoma).


Sign in / Sign up

Export Citation Format

Share Document